FREE Shipping on all US Orders
One million people just told science exactly what causes their hair loss. Here is what the data says.
Researchers just analysed the largest consumer hair loss dataset ever assembled — over one million users — using AI to find the patterns that predict who loses hair, when, and why. The three strongest predictors were not what the pharmaceutical industry has been treating for thirty years.
The largest hair loss dataset ever analysed confirms what Laritelle has always said: the three strongest predictors of hair loss are hormones, stress, and systemic health history. Not genetics alone. Not a DHT problem alone. A whole-body problem.
The hair loss industry has always operated on anecdote, small studies, and the assumptions of a medical model built primarily around middle-aged men with male-pattern baldness. For decades, the research base was thin, the clinical trials were small, and the understanding of who actually experiences hair loss — and why — was shaped more by who sought treatment than by who was actually affected.
That changed at the 2025 American Academy of Dermatology Innovation Academy, where researchers presented the largest consumer hair loss dataset ever analysed. One million and nine thousand, nine hundred and ninety-eight anonymised entries. Four years of data. AI-driven pattern recognition across age, gender, hormonal status, and medical history.
The findings confirm something practitioners in clinical aromatherapy and holistic hair loss have been observing for years. The dominant predictors of hair loss are not primarily genetic. They are hormonal, stress-related, and systemic. And the population most affected is not who the pharmaceutical industry built its treatments for.
The Data
What one million people actually showed.
The age progression data is particularly striking. Moderate to severe hair loss affected 25% of the 18–29 age group, rising to 41% in the 30–44 group, 54% in the 45–64 group, and 67% in those aged 65 and older. This is not the gradual decline the conventional model describes. Hair loss is beginning significantly earlier than most clinical frameworks acknowledge, and it accelerates through exactly the years when hormonal changes are most active.
Hormonal factors — postmenopausal and postpartum women showed the highest risk of any demographic group in the dataset. Not older men. Women in hormonal transition.
Stress history — a documented history of significant stress was among the strongest predictors of current hair loss severity, independent of age and hormonal status.
COVID-19 history — users with prior COVID-19 infection showed significantly elevated hair loss rates, consistent with the telogen effluvium pattern that post-viral illness is known to trigger.
None of these are genetic. All three are systemic. All three are addressable.
What This Changes
The dataset the pharmaceutical model wasn't built for.
The two FDA-approved hair loss treatments — minoxidil and finasteride — were developed primarily for androgenetic alopecia in men. Minoxidil was repurposed from a blood pressure medication. Finasteride was developed for enlarged prostate. Both have documented limitations in the population that the million-user dataset reveals as the most affected: women in hormonal transition.
Research published in the International Journal of Women's Dermatology indicates that estrogen and anti-androgen therapy stabilises follicle miniaturisation and increases shaft diameter in roughly 60–70% of post-menopausal women — but topical formulations like minoxidil are often selected to support follicle activity without addressing the underlying hormonal drivers.
This is the gap the dataset makes visible. The largest hair loss population is women experiencing hormonal transitions. The treatments most widely prescribed were not designed for them. The systemic drivers — hormonal, stress-related, post-viral — are not addressed by either approved drug. The industry has been answering the wrong question for thirty years, for a smaller population than the one actually experiencing the problem.
Postmenopausal and postpartum women showed the highest risk in the dataset. Both represent states of rapid hormonal shift — declining estrogen, altered progesterone, disrupted thyroid function, and relative DHT elevation as the protective estrogen buffer falls away.
Minoxidil widens blood vessels. It does not address estrogen decline. It does not modulate DHT at the follicle receptor. It does not support the hormonal environment that the follicle needs to stay in the growth phase. Laritelle's formulas — specifically Fertile Roots, formulated with clary sage, bhringaraj, nettle, and saw palmetto — address all three simultaneously. Not because Laritelle designed for this dataset specifically. Because the practitioners who formulated Laritelle understood what the million-user study has now confirmed at scale.
Stress history as a significant independent predictor of hair loss severity confirms what clinical aromatherapists and hair loss practitioners have observed consistently: the cortisol pathway is not a secondary factor in hair loss. It is a primary one, operating alongside and amplifying the hormonal drivers.
There is no FDA-approved pharmaceutical for stress-related hair loss. The cortisol pathway, the HPA axis, the sympathetic nervous system activation that reduces scalp blood flow and pushes follicles into premature telogen — none of these have a pharmaceutical solution. The intervention category that has the most clinical evidence for this pathway is the one the pharmaceutical model has spent decades dismissing: botanical aromatherapy, daily ritual, and the parasympathetic activation that consistent self-care produces.
COVID-19 history as a significant predictor represents a genuinely new finding at this scale. Post-viral telogen effluvium — the diffuse shedding that follows systemic illness two to four months later — has been documented in case studies and small cohorts. The million-user dataset confirms it as a population-level phenomenon.
The mechanism: systemic inflammation and oxidative stress from the viral illness damage the mitochondrial environment of follicle cells (connecting back to the PP405 energy metabolism research), push follicles into stress-induced telogen, and deplete the nutritional reserves that hair matrix production requires. The recovery pathway is the same one Laritelle addresses: circulation, antioxidant protection, anti-inflammatory botanical actives, and consistent daily support for the follicle environment.
The Age Curve
Why hair loss is starting earlier than anyone is acknowledging.
Twenty-five percent of the 18–29 age group in the dataset reported moderate to severe hair loss. This is not a rounding error. This is a quarter of young adults — predominantly women, given the dataset composition — experiencing significant hair loss in their twenties.
The conventional medical narrative frames hair loss as an aging phenomenon. The data frames it as a systemic health phenomenon that begins in young adulthood and accelerates through the hormonal transition years. The factors driving it in young adults are not primarily genetic either — they are stress, nutritional depletion, disrupted sleep, hormonal contraceptives, and the cumulative inflammatory load of modern life.
The most important intervention for this population is not a prescription. It is a daily practice that builds the follicle environment before the loss becomes visible. The microbiome study we covered earlier this week confirmed that scalp dysbiosis precedes visible hair loss. The aromatherapy cortisol data confirmed that eight weeks changes the biological record. The PP405 research confirmed that follicle dormancy is a metabolic energy problem that consistent support can address.
The million-user dataset ties all of it together: most people experiencing hair loss have systemic drivers that no single pharmaceutical was designed to address. The response is not a drug. It is a ritual.
The most important number in the dataset.
86.4% of the million users reported visible hair loss. Only 13.6% were in the early, pre-visible stage.
This means the vast majority of people who seek help have already moved through the window when intervention is most effective — when the microbiome is disrupted but the hair hasn't fallen yet, when the cortisol is elevated but the follicle is still producing, when the hormonal shift is underway but the shedding hasn't started.
The purpose of a daily botanical ritual is not to treat visible hair loss. It is to never get there. To maintain the follicle environment consistently enough that the biological cascade that leads to visible loss never reaches its conclusion. The million-user dataset is a description of what happens when that window is missed. The ritual is what you do while it is still open.
The answer was always systemic.
Built for the system — not the symptom.
Every Laritelle formula addresses the three drivers the data identified: hormonal, stress-related, and systemic. Daily. Before the drain fills.
→ Explore the Fertile Roots CollectionScience, ritual, and botanical intelligence — delivered daily.
Each morning, one article. New research, ancient wisdom, and the honest science of hair and scalp health. Written for women who want to understand what is happening — not just what to buy.
By subscribing you agree to receive email from Laritelle Organic. Unsubscribe at any time.